“Venturing Forward, Innovating for Impact” | Managing Partner | Venture Capital, Strategic M&A Advisory, Investment Banking | Board of Directors | Healthcare, Life Sciences, and Longevity
As we step into the second half of 2024, the biopharma sector stands resilient and optimistic. The first half of the year has already set a dynamic precedent, and there's a palpable sense of confidence and forward momentum with deal activity (and hopefully changes in interest rates later this year). Let’s explore the key factors driving this optimism and the trends shaping the biopharma deal landscape. I look forward to your input and keeping the dialogue going.
